Showing results (1-10 of 37) with videos related to
Sort By:
Pageof 4
Endocrine, Metabolic & Immune Disorders Drug Targets|December 17, 2008
Further LDL cholesterol lowering through targeting PCSK9 for coronary artery diseaseGuoqing Cao, Yue-Wei Qian, Mark C Kowala, et al.The Journal of Biological Chemistry|May 29, 2004
A feedback loop in the polo-like kinase activation pathwayEleanor Erikson, Timothy A J Haystead, Yue-Wei Qian, et al.Molecular Phylogenetics and Evolution|June 1, 2010
Genomic analysis of the carboxylesterases: identification and classification of novel formsEric T Williams, He Wang, Steven A Wrighton, et al.Biochemical and Biophysical Research Communications|November 15, 2011
Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradationYanqun Chen, He Wang, Lan Yu, et al.Journal of Immunological Methods|December 8, 2022
A sensitive and drug tolerant assay for detecting anti-AAV9 antibodies using affinity capture elutionEmma Simmons, Yi Wen, Jingling Li, et al.Heliyon|September 10, 2021
Angiopoietin-like protein 4 (ANGPTL4) is an inhibitor of endothelial lipase (EL) while the ANGPTL4/8 complex has reduced EL-inhibitory activityYan Q Chen, Thomas G Pottanat, Robert W Siegel, et al.Journal of Pharmacological and Toxicological Methods|February 6, 2008
Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterasesEric T Williams, Mariam E Ehsani, Xiliang Wang, et al.Biochemical and Biophysical Research Communications|November 26, 2020
Angiopoietin-like protein 4(E40K) and ANGPTL4/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4Yan Q Chen, Thomas G Pottanat, Robert W Siegel, et al.Journal of Lipid Research|March 25, 2021
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibitionYan Q Chen, Thomas G Pottanat, Eugene Y Zhen, et al.Bioanalysis|September 6, 2016
An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodiesJohn H Sloan, Richard G Conway, Thomas G Pottanat, et al.Pageof 4